Search results for "MESH: Prospective Studies"

showing 10 items of 17 documents

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

Medical pre-hospital management reduces mortality in severe blunt trauma: a prospective epidemiological study

2011

International audience; INTRODUCTION: Severe blunt trauma is a leading cause of premature death and handicap. However, the benefit for the patient of pre-hospital management by emergency physicians remains controversial because it may delay admission to hospital. This study aimed to compare the impact of medical pre-hospital management performed by SMUR (Service Mobile d'Urgences et de Réanimation) with non-medical pre-hospital management provided by fire brigades (non-SMUR) on 30-day mortality. METHODS: The FIRST (French Intensive care Recorded in Severe Trauma) study is a multicenter cohort study on consecutive patients with severe blunt trauma requiring admission to university hospital i…

MaleEmergency Medical ServicesTime FactorsMESH : AgedMESH : Prospective StudiesPoison controlCritical Care and Intensive Care Medicine0302 clinical medicineInjury Severity ScorePatient AdmissionEmergency medical services[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyMESH: Treatment OutcomeMESH: AgedMESH: Middle AgedMortality rate[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH : Patient AdmissionMESH : AdultMiddle Aged3. Good healthMESH : Wounds and InjuriesIntensive Care UnitsTreatment OutcomeBlunt traumaMESH: Young AdultBlunt traumaMESH: Emergency Medical ServicesInjury Severity ScoreMESH : Injury Severity ScoreFranceMESH: FirefightersMESH : Intensive Care UnitsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyAdolescentMESH : Male[SHS.INFO]Humanities and Social Sciences/Library and information sciencesMESH: Injury Severity ScoreMESH : Young AdultMESH : Treatment Outcome[SHS.INFO] Humanities and Social Sciences/Library and information sciencesMESH : Hospital Mortality03 medical and health sciencesYoung AdultIntensive careMESH : AdolescentmedicineHumansMESH : Emergency Medical ServicesMESH : Middle AgedMESH: Hospital MortalityIntensive care medicineMESH : FranceAgedMESH: AdolescentMESH: Humansbusiness.industryMESH: Patient AdmissionResearchMESH : HumansMESH: Time Factors030208 emergency & critical care medicineMESH: AdultMESH: MaleMESH: Prospective StudiesMESH: France[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesFirefightersEmergency medicineWounds and InjuriesMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH : FirefightersbusinessCritical Care
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Smoking and FOS expression from blood leukocyte transcripts in patients with coronary artery disease.

2011

International audience; OBJECTIVE: Analysis of the leukocyte transriptome, in particular the Finkel-Biskis-Jinkins Osteosarcoma (c-Fos) gene, which has a prominent role in inflammation, provides new insights into atherosclerosis mechanisms. Although smoking is a major risk factor, the links between smoking status and coronary artery disease (CAD) remains unclear. We aimed to analyze the relationship between smoking status and c-Fos expression in circulating leukocytes of patients with CAD. METHODS: c-Fos expression was measured by RT-Q-PCR, from blood leukocytes of 239 consecutive patients after acute myocardial infarction (MI). The patients were asked about their smoking status and stratif…

MaleMESH : RNA MessengerMESH: Chi-Square DistributionMESH : LeukocytesMESH : Prospective StudiesMESH : AgedMyocardial InfarctionSmoking PreventionMESH: Risk Assessmentc-FosMESH : Coronary Angiography0302 clinical medicineMESH : Genetic MarkersProspective StudiesMESH: Coronary Artery DiseaseAged 80 and over0303 health sciencesMESH: Middle AgedGenes fosMESH: Smoking Cessation3. Good healthMESH : SmokingMESH: Myocardial InfarctionOsteosarcomaSmoking statusCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyRisk AssessmentMESH: Leukocytes03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedRNA MessengerMESH : Coronary Artery DiseaseRisk factorMESH : Aged 80 and overAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionMESH : Smoking CessationMESH : Humansmedicine.diseaseMESH: Coronary AngiographyLinear ModelsMESH: FemaleBlood leukocyte transcriptomeMESH : Genes fos030204 cardiovascular system & hematologyMESH: Genetic MarkersBioinformaticsCoronary AngiographyCoronary artery diseaseMESH: Linear ModelsCoronary artery diseaseMESH: Aged 80 and overRisk FactorsMESH: Risk FactorsMESH : Linear ModelsLeukocytesMESH : FemaleMESH : Risk AssessmentMESH: Agedc-FosbiologySmoking[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMiddle AgedMESH : Risk Factors[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCardiologyFemaleFrancemedicine.symptomInflammation MediatorsMESH: SmokingMESH : MaleMESH: Inflammation MediatorsInflammationMESH: Genes fosMESH: Multivariate AnalysisMESH : Inflammation MediatorsInternal medicinemedicineIn patientMESH : France030304 developmental biologyMESH: RNA Messengerbusiness.industryMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesMESH: FranceMultivariate Analysisbiology.proteinSmoking CessationMESH : Myocardial Infarctionbusiness
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct

Effects of an eccentric training personalized by a low rate of perceived exertion on the maximal capacities in chronic heart failure: a randomized co…

2016

International audience; BACKGROUND: The eccentric (ECC) training, in spite of its potential interest (slightest request of the cardiorespiratory system) compared with the concentric (CON) training, is not applied during the rehabilitation of the chronic heart failure (CHF). The main reasons are the difficulty personalizing the ECC exercises by avoiding the muscle complications and the lack of information concerning the specific effects on the maximal capacities in CHF patients.AIM: To compare — following a prior study on the feasibility and on the functional impacts — the effects on maximal capacities and tolerance in CHF of ECC training tailored by a low rate of perceived exertion (RPE) an…

MaleMESH: Exercise Tolerancecoronary-artery-diseasegenetic structures[SDV]Life Sciences [q-bio]Heart RateCardiac diseasesProspective StudiesMESH: Cardiac RehabilitationMESH: Heart Ratehealth care economics and organizationsMESH: AgedCardiac RehabilitationExercise ToleranceMESH: Middle Aged6-minute walk testexerciseMESH: Muscle StrengthRehabilitationMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmuscle-contractionsExercise Therapy[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]adaptationsPhysical ExertioneducationHeart failureMESH: Physical Exertion[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH: Self ConceptexpressionHumansMESH: Exercise TherapyMuscle Strength[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]AgedMESH: HumansMESH: Chronic DiseasemortalitySelf ConceptMESH: MaleMESH: Prospective Studies[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Chronic DiseaseMESH: Heart FailureExercise Testresponsessense organsMESH: Exercise TestMESH: Femalefeasibilityinterval
researchProduct

Eubacterial PCR for Bacterial Detection and Identification in 100 Acute Postcataract Surgery Endophthalmitis

2008

International audience; PURPOSE: To evaluate eubacterial PCR compared with conventional cultures for detection and identification of bacterial agents in ocular samples from patients with acute postcataract endophthalmitis. METHODS: Broad-range eubacterial PCR amplification was used, followed by direct DNA sequencing in ocular samples (aqueous humor, vitreous samples from tap or vitrectomy) from 100 consecutive patients presenting with acute postcataract endophthalmitis. Bacterial cultures were performed on the same ocular samples by using traditional methods (brain-heart infusion broth). RESULTS: At the time of admission, the detection rate was not significantly different between cultures a…

MaleMESH: Sequence Analysis DNAMicrobiological culturegenetic structuresmedicine.medical_treatmentAntibioticsVitrectomy[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: Bacteriological TechniquesPolymerase Chain ReactionEye Infections Bacteriallaw.inventionPostoperative Complications0302 clinical medicineEndophthalmitislawRNA Ribosomal 16SMESH: Postoperative ComplicationsMedicineProspective StudiesComputingMilieux_MISCELLANEOUSPolymerase chain reactionMESH: AgedEndophthalmitis0303 health sciencesbiologyMESH: Eye Infections Bacterial3. Good healthMESH: RNA Ribosomal 16Smedicine.anatomical_structureAcute DiseaseMESH: Acute DiseaseFemaleDNA BacterialPars planamedicine.medical_specialtymedicine.drug_classMESH: Aqueous HumorAqueous Humor03 medical and health sciencesHumansMESH: Endophthalmitis[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyAgedBacteriological TechniquesPhacoemulsificationMESH: HumansBacteria030306 microbiologybusiness.industryMESH: Vitreous BodyMESH: Polymerase Chain ReactionSequence Analysis DNAEye infectionbiology.organism_classificationmedicine.diseaseMESH: DNA Bacterial[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: Prospective Studieseye diseasesSurgeryVitreous BodyMESH: Bacteria030221 ophthalmology & optometrysense organs[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologybusinessMESH: FemaleBacteriaMESH: PhacoemulsificationInvestigative Opthalmology & Visual Science
researchProduct

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.

2012

International audience; OBJECTIVE: Giant cell arteritis (GCA) is the most frequently occurring vasculitis in elderly individuals, and its pathogenesis is not fully understood. The objective of this study was to decipher the role of the major CD4+ T cell subsets in GCA and its rheumatologic form, polymyalgia rheumatica (PMR). METHODS: A prospective study of the phenotype and the function of major CD4+ T cell subsets (Th1, Th17, and Treg cells) was performed in 34 untreated patients with GCA or PMR, in comparison with 31 healthy control subjects and with the 27 treated patients who remained after the 7 others withdrew. RESULTS: Compared with control subjects, patients with GCA and patients wi…

MalePathologyMESH: Th17 CellsCellMESH : AgedMESH : Prospective StudiesMESH: Flow CytometryT-Lymphocytes RegulatoryPathogenesisMESH : T-Lymphocytes Regulatory0302 clinical medicineimmune system diseasesMESH : Th1 CellsImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyPharmacology (medical)MESH : FemaleProspective Studiesskin and connective tissue diseasesCells CulturedMESH: Aged0303 health sciencesMESH: Middle Agedmedicine.diagnostic_testMESH: Giant Cell ArteritisCell DifferentiationMESH : AdultMiddle AgedFlow CytometryMESH : NK Cell Lectin-Like Receptor Subfamily B3. Good healthMESH: NK Cell Lectin-Like Receptor Subfamily Bmedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleVasculitisMESH : Cell DifferentiationGlucocorticoidmedicine.drugNK Cell Lectin-Like Receptor Subfamily BMESH: Cells CulturedAdultMESH: Cell Differentiationmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Flow CytometryT cellMESH : MaleImmunologyGiant Cell ArteritisBiologyPolymyalgia rheumatica03 medical and health sciencesRheumatologyBiopsyMESH : Cells CulturedmedicineMESH : Th17 CellsHumansMESH : Middle Aged030304 developmental biologyAged030203 arthritis & rheumatologyMESH: HumansMESH: T-Lymphocytes RegulatoryMESH : HumansMESH: AdultTh1 Cellsmedicine.diseaseMESH : Giant Cell ArteritisMESH: Prospective StudiesMESH: MaleGiant cell arteritisMESH: Th1 CellsPolymyalgia RheumaticaMESH: Polymyalgia RheumaticaImmunologyTh17 CellsMESH : Polymyalgia RheumaticaMESH: Female
researchProduct